NCT02664415View on ClinicalTrials.gov

Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 4, 2017

Study Completion Date

August 4, 2017

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC01

40 mg/kg; administered IV

BIOLOGICAL

Placebo for VRC01

Sodium Chloride for Injection 0.9%, USP; administered IV

Trial Locations (1)

10330

SEARCH Thai Red Cross AIDS Research Centre Non-Network CRS, Bangkok

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02664415 - Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection | Biotech Hunter | Biotech Hunter